)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Avenue Therapeutics
Avenue Therapeutics (ATXI) investor relations material
Avenue Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Nov, 2026
Executive summary
Product candidates are ATX-04 for Pompe disease and IV tramadol for post-operative pain; no products are currently for sale, and operating losses are expected to continue.
Q3 net loss was $691,000; 9M net loss was $2.076 million versus $2.221 million in 2025, while 9M 2026 revenue was zero.
Financial highlights
Q3 operating expenses were $704,000 versus $724,000 YoY; R&D rose to $212,000 from $177,000, while G&A declined to $492,000 from $547,000.
9M operating expenses fell to $2.125 million from $3.735 million; the prior-year period included $1.404 million of AnnJi termination and transfer revenue.
Cash and equivalents were $1.520 million at September 30, 2026, versus $2.855 million at December 31, 2025; accumulated deficit was $107.6 million.
Outlook and guidance
R&D costs are expected to increase as ATX-04 development advances and regulatory work continues; operating losses are expected for at least the next several years.
FDA discussions are underway on a pivotal Pompe study design; after those discussions, funding is to be sought to finance and initiate the trial.
IV tramadol's next study depends on obtaining financing or a partnership; the development path is being evaluated.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Avenue Therapeutics
- Q2 2026 saw a $0.7M net loss, no revenue, and cash reserves drop to $1.9M.ATXI
Q2 2026 - Q1 2026 net loss narrowed, but ongoing funding needs and going concern risks persist.ATXIQ1 2026
- 2025 net loss narrowed to $2.9M as focus shifts to ATX-04 and IV tramadol amid funding challenges.ATXIQ4 2025
- All directors were elected and KPMG LLP was ratified as auditor for 2025.ATXIAGM 2025
- Seeks up to $35M to fund neurologic drug pipeline amid high risk and Fortress Biotech control.ATXIRegistration Filing
- Stockholders will elect directors, ratify KPMG as auditor, and review governance and compensation.ATXIProxy Filing
- Net loss narrowed to $2.2M as R&D costs fell and $1.4M revenue was recognized from AnnJi deal.ATXIQ3 2025
- AJ201 trial nears topline data as net loss narrows and funding needs persist.ATXIQ3 2024
- All director nominees, auditor ratification, and incentive plan amendments were approved.ATXIAGM 2024
Next Avenue Therapeutics earnings date
Q4 202625 Mar, 2027
Avenue Therapeutics
Next Avenue Therapeutics earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Avenue Therapeutics Inc is a U.S.-based specialty pharmaceutical company focused on the development and commercialization of treatments for acute and chronic pain. The company operates in the late-stage clinical development space, advancing non-opioid and opioid pain management therapies. Its strategy includes partnering for regulatory approval and market entry. The company is headquartered in Miami, Florida, and its shares are listed on the NASDAQ.